news
Dozens of anti-cancer compounds revealed by screening existing drugs
Researchers have screened thousands of existing drug molecules against cancer cell lines to discover almost 50 compounds that combat the condition.
List view / Grid view
Screening
news
Metal-based fragment molecule library to screen for drug candidates
Researchers have developed a novel metal-based fragment library of molecules that can be used to screen for new drug candidates.
news
Industry collaborate to screen existing drugs to repurpose for cystic fibrosis
In an effort to address some of the more serious untreatable infections encountered by patients with cystic fibrosis, Calibr will collaborate with the Cystic Fibrosis Foundation on a two-year project.
news
Screening platform reveals compounds that protect neuronal mitochondria
Researchers have developed a screening system and identified a set of compounds that protect neuronal mitochondria in mice.
whitepaper
ebook: The ELISA Guide – to your successful experiments
Enzyme Linked Immunosorbent Assays (ELISAs) are one of the most common immunoassays on the market.
news
Computational model of molecular interactions could improve new medicine development
Researchers have produced a mathematical framework enabling quick assessment of how different parameters control interactions between molecules with multiple binding sites.
news
Organoid models for personalised treatments of glioblastomas developed
Lab-grown brain organoids from patients’ glioblastomas could be useful models to rapidly test and identify effective personalised treatments, find researchers.
news
Assay for reading six molecular pathways simultaneously developed
Researchers have developed a luciferase assay that can be used to monitor the effects of treatments on six different molecular targets at once.
article
CRISPR: kick-starting the revolution in drug discovery
Gene editing using the CRISPR system has been established as the most powerful tool in the search for new drugs and is now being exploited for therapeutic purposes. Here, Pushpanathan Muthuirulan discusses the promises and wider opportunities of using CRISPR technology to open up the possibility of large-scale screening of…
article
Open innovation – a collaboration between academia and the pharmaceutical industry to further leverage drug discovery expertise and assets
Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs. AstraZeneca’s Marian Preston, David Murray and Mark Wigglesworth discuss how this can not only drive innovation but also prove successful in identifying lead compounds, as evidenced through recent collaborations.
whitepaper
Application note: CAR T Cell Research
Chimeric antigen receptor (CAR) T cell transfer has had success as a treatment for leukemia and lymphoma, but solid tumors have been more challenging due to the rarity of true tumor-specific target molecules and the immunosuppressive nature of the tumor microenvironment.
article
Expert view – The Octet HTX system: enabling multi-purpose screening of therapeutic biologics during development
Current trends in the development of therapeutic biologics suggest that engineered molecules such as bispecific antibodies and antibody-drug conjugates are the future of the industry, yet despite this, monoclonal antibody (mAb) development remains a dominant focus.
article
Expert view: Promising methods in kinase screening
Kinase-mediated phosphorylation is a control point for nearly all activity within a cell, making kinases important in many diseases.
article
Screening In-Depth Focus 2019
In this In-Depth Focus are articles investigating how CROs can help to drive innovation and how CRISPR technologies could be used for drug screening purposes.
article
Drug Target Review – Issue 4 2019
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.